Clinical trials: Advanced Malignant Tumor
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Gynecologic Cancer, Immunotherapy
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation.
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Trial name
- NCT04957511
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Viome
Solid Tumors
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.
- Trial name
- NCT04642365
- Testing
- RO7296682, Atezolizumab
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
Advanced Solid Tumor
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
This is a multi-center phase II clinical trial to evaluate the anti-tumor activity and safety of HX009 in subjects with advanced solid tumors.
- Trial name
- NCT04886271
- Testing
- HX009
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Non-small Cell Lung Cancer, Lung Cancer
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
- Trial name
- NCT06644768
- Testing
- valemetostat tosylate, pembrolizumab
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 137 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor
Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
RATIONAL: Simmitecan is an anticancer ester prodrug, which involves activation to chimmitecan. Chimmitecan，a novel CPT derivative, exhibited potent antitumor activities both in vitro and in vivo by inhibiting topoisomerase I.
- Trial name
- NCT01832298
- Testing
- Simmitecan Hydrochloride for Injection
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Advanced Solid Tumor
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TT-00973-MS tablets in patients with solid tumors.
- Trial name
- NCT05673538
- Testing
- TT-00973-MS tablets treatment
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors
- Trial name
- MEETCD8-001 (NCT05707676)
- Testing
- LB4330
- Where
- China
- Volunteers
- 40 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Cancer, Solid Tumor
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors.
- Trial name
- NCT02937116
- Testing
- IBI308, IBI308\Cisplatinum\Pemetrexed, IBI308\cisplatin\gemcitabine
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor Malignancy
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Stage 1 (Safety study for 68Ga-NRT6020 Injection): The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors.
- Trial name
- NCT06911489
- Testing
- 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection (stage 2), 177Lu-NRT6020 Injection (stage 3)
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
MSI-H or dMMR Advanced Solid Tumors
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
This study is designed to evaluate the efficacy and safety of Anlotinib combined with AK105 injection or AK105 monotherapy in subjects with MSI-H or dMMR advanced solid tumors.
- Trial name
- NCT04291248
- Testing
- AK105, Anlotinib
- Where
- 9 sites in China
- Volunteers
- 138 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Malignant Mesothelioma
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Trial name
- NCT00027508
- Testing
- trabectedin
- Where
- 4 sites in United States
- Sponsor
- PharmaMar
Advanced Malignancies
Phase I Study of XZ120 in Malignant Tumors
This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast…
- Trial name
- NCT06206915
- Testing
- XZ120 injection
- Volunteers
- 123 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Advanced Solid Tumor
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum…
- Trial name
- NCT06621615
- Testing
- CVL006 Injection
- Volunteers
- 120 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
A Study of CS1002 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
- Trial name
- NCT03523819
- Testing
- CS1002, CS1003
- Where
- 10 sites in Australia, Hong Kong
- Volunteers
- 91 people
- Sponsor
- CStone Pharmaceuticals
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.